Featured Articles
Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
![icon1](https://oncosec.com/wp-content/uploads/2020/01/icon1.png)
Clinical Pipeline
Our core technology platform continues to advance through clinical trials for various cancers
Learn More
![icon2](https://oncosec.com/wp-content/uploads/2020/01/icon2.png)
Technology
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer
Learn More
![icon3](https://oncosec.com/wp-content/uploads/2020/01/icon3.png)
Partnerships
We have a track record of establishing, operating and evolving high-performance partnerships globally
Learn More